Welcome to our dedicated page for PERKINELMER news (Ticker: PKI), a resource for investors and traders seeking the latest updates and insights on PERKINELMER stock.
PerkinElmer Inc. (symbol: PKI) is a leading global provider of solutions that enable scientists, researchers, and clinicians to tackle complex challenges in science and healthcare. The company's mission is to innovate for a healthier world through unique solutions that serve the diagnostics, life sciences, food, and applied markets.
PerkinElmer collaborates closely with its customers to deliver earlier and more accurate insights. This is supported by the company's deep market knowledge and technical expertise. With a dedicated workforce of approximately 14,000 employees worldwide, PerkinElmer is committed to improving the quality of life, creating healthier families, and sustaining the wellbeing and longevity of people globally.
In 2020, PerkinElmer reported revenues of approximately $3.8 billion and serves customers in 190 countries. Notably, the company is a component of the S&P 500 index, underscoring its significant market presence and financial stability.
Recent Achievements and Current Projects
- Strategic partnerships with key industry players to enhance diagnostic solutions and life sciences research.
- Continuous investment in innovative technologies and solutions that drive earlier and more accurate healthcare insights.
- Expansion of global reach through new product launches tailored to various market needs.
PerkinElmer's commitment to innovation and collaboration makes it a crucial player in the healthcare and scientific research sectors. By leveraging its extensive expertise and comprehensive solutions, the company strives to address the most pressing challenges faced by its customers.
PerkinElmer (NYSE: PKI) has launched the BioQule™ NGS System, an innovative benchtop solution for next-generation sequencing (NGS) library preparation. This system allows labs to automate the process for up to eight samples, featuring integrated quality control and liquid handling technology. Unlike existing solutions, the BioQule provides in-built quantification of created libraries and requires only 10 ng of starting material. It is suitable for various lab sizes and does not necessitate prior automation experience. The system will be showcased at the AGBT General Meeting in Orlando from June 6-9, 2022.
PerkinElmer reports Q1 2022 revenue of $1.26 billion, down from $1.31 billion a year prior. GAAP EPS from continuing operations is $1.40 compared to $3.37 in Q1 2021. The company initiates guidance for Q2 2022, forecasting revenue of $1.20-1.22 billion and expects adjusted EPS between $2.00-2.05. For the full year, expected revenue is $4.56-4.63 billion with adjusted EPS of $7.15-7.45. Despite revenue declines, the company highlights significant growth in the Discovery & Analytical Solutions segment with a 33% increase.
PerkinElmer, Inc. (NYSE: PKI) has declared a quarterly dividend of $0.07 per share, to be paid on August 12, 2022. This dividend is for shareholders on record as of July 22, 2022. In 2021, the company reported approximately $5 billion in revenue and employs over 16,000 individuals, serving customers across 190 countries. PerkinElmer is part of the S&P 500 Index, indicating its significant presence in the market.
PerkinElmer, Inc. (NYSE: PKI) will announce its first quarter 2022 financial results after market close on May 3, 2022. The company will host a conference call that same day at 5:00 p.m. ET to discuss the results, led by CEO Prahlad Singh and CFO Jamey Mock. Investors can access the call through a live audio webcast available on the company's website, with a replay starting at 7:00 p.m. ET the same day. PerkinElmer reported approximately $5.0 billion in revenue in 2021 and operates in 190 countries.
PerkinElmer, Inc. (NYSE: PKI) has launched the Vega® imaging system, an innovative automated ultrasound platform aimed at enhancing preclinical research in cancer, liver and kidney diseases, and cardiology. The system allows for hands-free operation and high-throughput scanning, improving research efficiency. Key features include advanced imaging modes for better visualization of diseases and therapies. This technology was acquired through PerkinElmer's purchase of SonoVol, Inc. The company recently reported revenues near $5 billion in 2021, supporting its position in the S&P 500.
PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.
PerkinElmer, a leader in health innovation, will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference. The Cowen conference is scheduled for March 7, 2022, with Jamey Mock, CFO, presenting at 10:30 a.m. ET. Following this, Prahlad Singh, CEO, will present at the Barclays conference on March 15, 2022, at 1:30 p.m. ET in Miami. Both presentations will provide insights on the company's strategic priorities, with live audio webcasts available on their website, where replays will also be accessible for 90 days post-event.
PerkinElmer, a leader in health innovation, will present at Citi’s Virtual Healthcare Conference on February 24, 2022, at 8:45 a.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. Interested participants can register here. A live webcast will also be available on the Investors section of the company’s website, with a replay accessible for 90 days post-event.
PerkinElmer reported $5.0 billion in revenue for 2021 and operates in 190 countries.
EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.
PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.
FAQ
What is the market cap of PERKINELMER (PKI)?
What does PerkinElmer Inc. do?
What is the mission of PerkinElmer Inc.?
How many employees does PerkinElmer Inc. have?
What was PerkinElmer Inc.'s revenue in 2020?
In how many countries does PerkinElmer Inc. serve customers?
What are some of PerkinElmer Inc.'s recent achievements?
How does PerkinElmer Inc. contribute to healthcare?
Is PerkinElmer Inc. part of any major stock index?
What markets does PerkinElmer Inc. serve?
What is a core focus of PerkinElmer Inc.'s partnerships?
